BioSpace News Archive

Biotech Bay

Gilead Updates 2020 Guidance with Post-Holiday COVID-19 Spike

Gilead is projecting remdesivir sales of about $2.825 billion alone for 2020.

January 12, 2021
·
3 min read
·
Mark Terry
Career Advice

4 Tips for Successfully Onboarding to a New Company Remotely

How do you find success (and not feeling like you’re drowning) when you have to onboard to a new job virtually? We have a few ideas.

January 12, 2021
·
2 min read
·
Laura Brothers
Business

JPM2021: BioNTech Aims for 2 Billion COVID-19 Vaccine Doses by End of 2021 and More

BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.

January 12, 2021
·
4 min read
·
Alex Keown
Business

Enara Bio, Boehringer Ingelheim Agree to Collab on Immunotherapy Discovery Research

The collaboration, which will leverage Enara’s Dark Antigen™ discovery platform, will work toward discovering and validating novel “Dark Antigens” in up to three tumor types in both lung and gastrointestinal cancer.

January 12, 2021
·
3 min read
·
Brandon May
Drug Development

Herd Immunity to COVID-19 Likely Will Not Be Achieved in 2021, Experts Suggest

The advancing rollout of currently approved coronavirus disease 2019 (COVID-19) vaccines provides hope to many that existing lockdowns and social restrictions will soon be lifted, but experts suggest a “return to normal” likely won’t occur until herd immunity is achieved.

January 12, 2021
·
2 min read
·
Brandon May
Drug Development

2021 Biopharma Update on the Novel Coronavirus: January 12

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.

January 12, 2021
·
4 min read
·
BioSpace Editorial Staff
Business

Novartis Adds BeiGene’s Checkpoint Inhibitor to Oncology Arsenal

Novartis plunked down $650 million in upfront payment for BeiGene’s Tislelizumab, which is already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China.

January 12, 2021
·
3 min read
·
Alex Keown
Business

Sanofi Keeps on Rolling With Biond Biologics Partnership

The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells.

January 12, 2021
·
3 min read
·
Heather McKenzie
Vertex Looks to Expand Portfolio with Mid- and Late-Stage Assets

On Monday, at the JP Morgan Healthcare Conference held virtually, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”

January 12, 2021
·
3 min read
·
Mark Terry
Drug Development

COVID-19 Vaccine Makers That Have Seen Large Stock Spikes in Past Year

Publicly-traded companies that have been heavily involved in developing therapies and vaccines for COVID-19 have seen significant spikes in their stock prices over the past 10 months, including Germany’s BioNTech, which has surged 187% in one year.

January 12, 2021
·
3 min read
·
Alex Keown